We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
- Authors
US Preventive Services Task Force; Bibbins-Domingo, Kirsten; Grossman, David C; Curry, Susan J; Davidson, Karina W; Epling, John W Jr; García, Francisco A R; Gillman, Matthew W; Kemper, Alex R; Krist, Alex H; Kurth, Ann E; Landefeld, C Seth; LeFevre, Michael L; Mangione, Carol M; Phillips, William R; Owens, Douglas K; Phipps, Maureen G; Pignone, Michael P
- Abstract
<bold>Importance: </bold>Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.<bold>Objective: </bold>To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults.<bold>Evidence Review: </bold>The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events.<bold>Conclusions and Recommendations: </bold>The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).
- Subjects
STATINS (Cardiovascular agents); ANTICHOLESTEREMIC agents; CARDIOVASCULAR disease related mortality; DYSLIPIDEMIA; U.S. Preventive Services Task Force; CARDIOVASCULAR disease prevention; AGE distribution; ANTILIPEMIC agents; COMPARATIVE studies; HYPERLIPIDEMIA; RESEARCH methodology; MEDICAL cooperation; MEDICAL screening; PREVENTIVE health services; RESEARCH; RISK assessment; EVALUATION research; DISEASE complications; DIAGNOSIS
- Publication
JAMA: Journal of the American Medical Association, 2016, Vol 316, Issue 19, p1997
- ISSN
0098-7484
- Publication type
journal article
- DOI
10.1001/jama.2016.15450